Today osteoarthritis constitutes the most common cause of musculoskeletal disability across the globe and one of the heaviest burdens on public health services in any country.
Osteoarthritis is a degenerative disease of the joints associated with the progressive deterioration and wearing away of the cartilage and disorders in the nearby structures, especially the bone. It is most frequently found in the hands, hips, knees and spine and is probably the most common disease of all after the age of 65. The basic clinical signs are pain, stiffness and progressive functional limitation, which may be associated with varying degrees of deformity. All over the world this disease is increasing due to the ageing of the population.
Osteoarthritis’ treatment must simultaneously control the pain and slow down the process of joint degeneration. Today, new treatments based on hyaluronic acid can counteract cartilage deficits, enhance the spontaneous repair processes and effectively control pain.
The treatment, entailing the infiltration of hyaluronic acid in a joint, is called viscosupplementation and its benefits have been widely demonstrated.
Pharmacological treatments for osteoarthritis are rapidly and effectively increasing, so that today, they can guarantee brilliant results in terms of efficacy. Helping to relieve the symptoms of osteoarthritis also for a long time, viscosupplementation allows to avoid or delay joint replacement surgery and to maintain an active lifestyle.
A safe and cutting-edge technology
Viscosupplementation is more effective when the characteristics of the administered hyaluronic acid solution mimic those of the natural synovial fluid. At IBSA we have put all our knowledge and resources with the aim to develop and provide innovative and unique solutions that could be tailored to different needs. One of the latest results of our innovation-driven approach to research and quality is the NAHYCO® HYBRID TECHNOLOGY.
A treatment with products based on the IBSA NAHYCO® HYBRID TECHNOLOGY is able to convey high quantities of hyaluronic acid, optimising the viscous and elastic properties of the formulation and improving its resistance to the action of hyaluronidases through polymer chains of high and low molecular weight hyaluronic acid (L-HA).
This innovative treatment allows for a high concentration of HA to be reached, without compromising ease and safety of the procedure (injection), while effectively mimicking the physical and mechanical properties of healthy synovial fluid.
Moreover, IBSA’s high quality hyaluronic acid is produced by multiphase biofermentation and does not contain any animal-derived ingredients. Its added value, therefore, is that it is a hypoallergenic product capable of preventing the transmission of pathogens.
SINOVIAL® HL
Thanks to the NAHYCO® patented production process IBSA has developed the innovative SINOVIAL® HL pre-filled syringes for intra-articular injection, indicated for pain or reduced mobility due to degenerative diseases (arthrosis), post-traumatic diseases and tendinopathy associated with joint disabilities. Its administration brings a marked reduction in pain, improved joint mobility, and reduced use of rescue medication. Its efficacy is already evident starting from the first injection and it lasts up to 6 months, suggesting a long-lasting carry-over effect of the treatment. This characteristic allows to minimize the risks of infection caused by the injections themselves and by multiple rounds to the clinic.
SINOGEL®
In Sinogel® high molecular weight hyaluronic acid is enriched by the presence of chondroitin – a substance naturally present in the connective tissues of the human body – in the highest percentage on the market today. Thanks to NAHYCO® patented procedure, the hyaluronic acid and chondroitin interact with each other, giving the solution special rheological characteristics.
Sinogel® is indicated for pain or reduced mobility due to degenerative diseases, post-traumatic conditions, joint and tendons disorders and particularly for the viscosupplementation of the hip osteoarthritis (OA).
Re-establishing naturally the viscoelastic properties of the synovial fluid, its administration reduces the pain quickly and improves joint and tendon mobility.
Sinogel® has a number of unique properties that make it a premium product:
- Large volume of solution (3 ml) advisable for the viscosupplementation of large joints
- The highest quantity of glycosaminoglycans (GAGs) in the market
- Optimal viscosity for ease of use and injection
- The only HA intra-articular injection in the market produced by NAHYCO® HYBRID TECHNOLOGY
WHO IS IBSA
IBSA is one of the world leaders in the production of hyaluronic acid by bio-fermentation and a leading brand in the world of viscosupplementation products for osteoarthritis & MSK pathologies. Since 1985, an extraordinary development programme has enabled the multinational pharmaceutical company to grow its assets to cover 10 main therapeutic areas, achieving a leading position in world markets. IBSA is constantly renewing its product portfolio, patenting and improving formulations and technologies that respond to and satisfy market demand and is constantly looking for partners and international distributors for licensing agreements in countries where IBSA does not operate directly with its branches.
